More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$4.79B
P/E ratio
30.6
Dividend yield
1.03%
Expense ratio
0.37%
Beta
0.546546
Previous close
$78.43
Today's open
$77.67
Day's range
$77.09 - $78.11
52 week range
$59.63 - $80.71
Industries
Health
Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction
I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those addressing hard-to-treat diseases with novel approaches. Recent regulatory headwinds have eased, derisking select names and enabling ground-floor entry after a sector-wide sell-off.
Seeking Alpha • Nov 9, 2026

IYH and XBI: Two Distinct Paths to Investing in Healthcare
iShares U.S. Healthcare ETF tracks a broad mix of pharmaceutical and medical device companies, while State Street SPDR S&P Biotech ETF focuses strictly on the biotechnology sub-industry. State Street SPDR S&P Biotech ETF has delivered a higher 1-year total return but experienced a significantly deeper maximum drawdown of 53.2%.
The Motley Fool • Nov 7, 2026

Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
U.S. midterm results signal a "Blue Wave," with Democrats controlling both House and Senate, likely impacting healthcare policy and funding. Health insurers like UnitedHealth and CVS Health typically rebound after policy shocks; Oscar Health stands out for ACA-driven growth and innovation.
Seeking Alpha • Nov 5, 2026

Democrats Win: Time to Shift from AI to Consumer & Healthcare ETFs?
Democrats' midterm gains could add to AI stocks' regulatory woes, making consumer and healthcare ETFs worth watching.
Zacks Investment Research • Nov 5, 2026

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
Launched on June 12, 2000, the iShares U.S. Healthcare ETF (IYH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.
Zacks Investment Research • Oct 26, 2026

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF
Vanguard Health Care ETF provides significantly broader exposure with 411 holdings compared to 100 for iShares U.S. Healthcare ETF. The Vanguard fund maintains a lower expense ratio of 0.09%, while the iShares fund charges 0.37%.
The Motley Fool • Oct 21, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200 biotech companies, while the iShares U.S. Healthcare ETF holds 100 diverse healthcare positions.
The Motley Fool • Oct 11, 2026

IYH Beats IXJ on Returns While Global Fund Offers Higher Yield
iShares Global Healthcare ETF provides broad exposure to international medical companies with a higher dividend yield than its domestic counterpart. iShares U.S. Healthcare ETF concentrates on American companies and has produced higher total returns over the past year and five-year periods.
The Motley Fool • Oct 6, 2026

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH
The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF provides broader industry diversification across the medical sector, while the Invesco Nasdaq Biotechnology ETF focuses strictly on biotechnology and pharmaceuticals.
The Motley Fool • Sep 23, 2026

5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.
Seeking Alpha • Sep 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell iShares U.S. Healthcare ETF commission-free¹. Build wealth for the long term using automated trading and transfers.